Molecular characterization of Plasmodium falciparum uracil-DNA glycosylase and its potential as a new anti-malarial drug target
© Suksangpleng et al.; licensee BioMed Central Ltd. 2014
Received: 27 September 2013
Accepted: 1 April 2014
Published: 17 April 2014
Based on resistance of currently used anti-malarials, a new anti-malarial drug target against Plasmodium falciparum is urgently needed. Damaged DNA cannot be transcribed without prior DNA repair; therefore, uracil-DNA glycosylase, playing an important role in base excision repair, may act as a candidate for a new anti-malarial drug target.
Initially, the native PfUDG from parasite crude extract was partially purified using two columns, and the glycosylase activity was monitored. The existence of malarial UDG activity prompted the recombinant expression of PfUDG for further characterization. The PfUDG from chloroquine and pyrimethamine resistant P. falciparum strain K1 was amplified, cloned into the expression vector, and expressed in Escherichia coli. The recombinant PfUDG was analysed by SDS-PAGE and identified by LC-MS/MS. The three dimensional structure was modelled. Biochemical properties were characterized. Inhibitory effects of 12 uracil-derivatives on PfUDG activity were investigated. Inhibition of parasite growth was determined in vitro using SYBR Green I and compared with results from human cytotoxicity tests.
The native PfUDG was partially purified with a specific activity of 1,811.7 units/mg (113.2 fold purification). After cloning of 966-bp PCR product, the 40-kDa hexa-histidine tagged PfUDG was expressed and identified. The amino acid sequence of PfUDG showed only 24.8% similarity compared with the human enzyme. The biochemical characteristics of PfUDGs were quite similar. They were inhibited by uracil glycosylase inhibitor protein as found in other organisms. Interestingly, recombinant PfUDG was inhibited by two uracil-derived compounds; 1-methoxyethyl-6-(p-n-octylanilino)uracil (IC50 of 16.75 μM) and 6-(phenylhydrazino)uracil (IC50 of 77.5 μM). Both compounds also inhibited parasite growth with IC50s of 15.6 and 12.8 μM, respectively. Moreover, 1-methoxyethyl-6-(p-n-octylanilino)uracil was not toxic to HepG2 cells, with IC50 of > 160 μM while 6-(phenylhydrazino)uracil exhibited cytoxicity, with IC50 of 27.5 μM.
The recombinant PfUDG was expressed, characterized and compared to partially purified native PfUDG. Their characteristics were not significantly different. PfUDG differs from human enzyme in its size and predicted amino acid sequence. Two uracil derivatives inhibited PfUDG and parasite growth; however, only one non-cytotoxic compound was found. Therefore, this selective compound can act as a lead compound for anti-malarial development in the future.
KeywordsPlasmodium falciparum Malaria Uracil-DNA glycosylase Antimalarials Drug target
Malaria is an important infectious disease caused by Plasmodium parasites, for which Plasmodium falciparum is found prevalently and causes virulent symptoms. The disease is endemic in more than 100 countries and causes approximately 655,000 deaths worldwide . The most serious problem for malaria treatment is the development of resistance of the parasites to existing anti-malarial drugs including the most effective drug, artemisinin, which has been used as first-line treatment in many countries [1–6].
The discovery of new drug targets would be an effective strategy for combating multidrug resistant malaria. Many enzymes involved in biosynthesis and metabolic processes such as membrane biosynthesis [7, 8], membrane transport , proteases [10–12], redox system [13, 14] and mitochondrial system [15, 16] have been investigated for their potential as anti-malarial drug targets. However, very little is known about malarial DNA repair system and its significance.
DNA repair is essential for parasite existence to prevent gene mutations by both spontaneous mutation during DNA replication of cell division and drug-induced mutation. Base excision repair (BER), for example, plays a major role in removing a damaged base followed by replacement of the correct base into DNA [17, 18]. Therefore, enzymes involved in BER should be explored for their roles as new drug targets against malaria. DNA glycosylases are the first enzymes in the BER pathway, and recognizing specific damaged bases, they act as the key enzymes to drive the BER process. Uracil-DNA glycosylase (UDG) is a specific DNA glycosylase for uracil cleavage. This base is introduced by cytosine deamination, which occurs as frequently as 100–500 times/cell/day ; therefore, this enzyme plays very important role in preventing G:C to A:T transition mutation.
UDGs of many organisms have been characterized for their biochemical properties, for example the bacterial enzymes (Escherichia coli[20, 21]), viral enzymes (poxvirus , HSV-1 ), parasite enzyme (Trypanosoma cruzi), and human enzyme [25–27]. Moreover, UDG inhibitors should be considered for targeting to PfUDG. Two types of UDG inhibitors, uracil glycosylase inhibitor (UGI) protein and uracil-derived compounds have been studied. The UGI is a well-known UDG inhibitor isolated from bacteriophage PBS 1 and 2 specific to Bacillus subtilis. This protein inhibited UDG of several organisms [28–31]. The uracil-derived compounds, 6-(p-alkylanilino)uracils, were reported to inhibit HSV-1 UDG by acting as uracil analogs to bind competitively to the catalytic amino acid residues in the active site motif of UDG [23, 32, 33].
Because UDG is essential for conservation of genome integrity and normal function of encoding proteins of organisms including the malaria parasite, P. falciparum, therefore in this study P. falciparum UDG (PfUDG) was successfully cloned and expressed, and the native enzyme was also partially purified. PfUDG activity was determined, and properties of both recombinant and native enzymes were characterized. Inhibitory effects of 12 uracil-derived compounds on enzyme and parasite growth were investigated, and their cytotoxicities were determined. Results obtained were promising for further design of a new anti-malarial drug against P. falciparum, especially against drug resistant strains worldwide.
Preparation of partially purified native PfUDG
Plasmodium falciparum K1 strain, a chloroquine and pyrimethamine resistant strain from Thailand , was cultured in RPMI 1640 (Invitrogen, CA, USA) supplemented with 10% human serum and human red blood cells (RBC) at 37°C in an atmosphere containing 5% CO2. The RBC-packed parasites with 20-25% parasitaemia were harvested by centrifugation at 664xg at 25°C for 7 min. The parasite pellet was prepared by incubation of RBC-packed parasites with an equal volume of phosphate buffered saline (PBS), pH 7.6, containing 0.15% (w/v) saponin at 37°C for 20 min. The suspension was washed with PBS by centrifugation at 664xg at 25°C for 10 min until the supernatant was clear, and the parasite pellet was kept at -80°C until used.
Approximately 2 ml of parasite pellet was resuspended in three volumes of extraction buffer containing 50 mM Tris–HCl pH 7.6, 1 mM EDTA, 2 mM DTT, 1 mM PMSF, and 0.01% NP-40. Parasite cells in suspension were disrupted by Dounce homogenization, and nucleoprotein was extracted by 0.5 M KCl with stirring on ice for 30 min. The suspension was centrifuged at 17,600xg for 40 min at 4°C, and the supernatant was dialysed at 4°C overnight against buffer A containing 25 mM Tris–HCl pH 9.0, 1 mM EDTA, 2 mM DTT, 1 mM PMSF, 0.01% NP-40, 5% sucrose, and 20% glycerol.
Partial purification of native PfUDG
The dialysed crude extract was loaded onto a 1 ml HiTrap™Capto™Q (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) column, and purified by using FPLC®System (Pharmacia Biotech AB, Uppsala, Sweden) at a flow rate of 1 ml/min at 4°C. The unbound fractions were collected, and the column was washed with 10 column volumes (CV) of buffer A. The bound proteins were then eluted with 15 CV of 0-100% KCl linear gradient in buffer A. Both unbound and bound fractions were assayed for UDG enzymatic activity. The fractions containing PfUDG were pooled and dialysed at 4°C overnight against buffer B containing 50 mM HEPES pH 8.5, 1 mM EDTA, 2 mM DTT, 1 mM PMSF, 0.01% NP-40, 5% sucrose, and 20% glycerol. The dialysed fraction was then loaded onto a 1 ml Hitrap™ Heparin HP (GE Healthcare Bio-Sciences AB) column at a flow rate of 0.5 ml/min at 4°C. The unbound proteins were collected and the column was washed with 10 CV of buffer B. The column was then eluted with 15 CV of 0-100% KCl linear gradient in buffer B. Fractions containing PfUDG were pooled and termed native PfUDG.
Construction of PfUDG expression vector
The genomic DNA P. falciparum K1 strain was the source of genomic DNA used as a template in PCR to generate full-length PfUDG. The full-length gene was amplified by using specific primers: PfUDG-forward 5'-CACCATGAATAATCCAACAATT-3' and PfUDG-reverse 5'-TTGGGGTAGCTCCCATTTG-3'. The amplification was done by initial denaturing at 95°C for 5 min followed by 35 cycles of reaction with denaturing at 95°C for 1 min, annealing at 58°C for 1 min, extension at 72.5°C for 1 min after each cycle, and final extension at 72.5°C for 3 min. The PCR product was analysed by 1% agarose gel electrophoresis. The amplified full-length PfUDG was cloned into pET101/D-TOPO expression vector using Champion™pET Directional TOPO Expression System (Invitrogen) at a 1.5 to 1 molar ratio of the gene fragment and the vector. The constructed vector was named pET101D-PfUDG, and the sequence was analysed for base sequence correction by BioDesign, Pathumthani, Thailand.
Expression and purification of recombinant PfUDG
The pET101D-PfUDG vector was transformed into E. coli Rosetta (DE3) pLysS and grown on LB agar containing 100 μg/ml ampicillin and 20 μg/ml chloramphenicol at 37°C overnight. A single colony was picked and grown in 10 ml of LB broth containing 100 μg/ml ampicillin and 20 μg/ml chloramphenicol at 37°C overnight. The overnight culture was inoculated into 1 L of LB broth containing 0.5 M sorbitol, 100 μg/ml ampicillin and 20 μg/ml chloramphenicol, and incubated at 37°C with shaking at 180 rpm until the optical density at 600 nm reached 0.4. PfUDG expression was induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and bacteria were further incubated at 37°C with shaking for 1 hr. The bacteria were then harvested by centrifugation at 1,600xg for 20 min, washed with buffer, pH 8.0, containing 50 mM NaH2PO4 and 300 mM NaCl, and centrifuged at 1,600xg for 20 min. The bacterial pellet was resuspended in 200 ml of cold lysis buffer, pH 8.0, containing 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, and 1 mM PMSF, and disrupted by a XL 2020 Sonicator® Ultrasonic Processor XL (Heat System Inc., NY, USA). The total soluble protein was fractionated by centrifugation at 17,600xg at 4°C for 20 min. The expressed protein was analysed by SDS-PAGE.
The total soluble protein was loaded onto a Ni-NTA agarose affinity column (QIAGEN, Hilden, Germany) pre-equilibrated with 10 CV of cold lysis buffer with gravity flow. The column was washed continuously with 12 CV of cold washing buffer, pH 8.0, containing 50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, and 1 mM PMSF, and protein was then eluted with 8 CV of cold eluting buffer, pH 8.0, containing 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, and 1 mM PMSF. The flowthrough, washed and eluted fractions were collected, and protein concentration was measured by Bradford’s assay (Bio-Rad Laboratories, CA, USA). The protein purity was analysed using SDS-PAGE.
Identification of PfUDG by LC-MS/MS and 3D modelling of PfUDG
The expected protein bands were cut from the gel and digested with trypsin to get peptide fragments. The pattern of peptide fragments and amino acid sequences were analysed using LC-MS/MS and identified by MASCOT software . The 3D structure of PfUDG was built from predicted amino acid sequences of the full-length PfUDG protein compared to human UDG PDB code 3FCF using SWISS MODEL modelling server in http://swissmodel.expasy.org[36–38]. Geometry optimization was performed in a water box plus ions, and geometry of conformers was validated by PROCHECK .
Preparation of UDG activity assay substrates
Composition of single stranded oligonucleotides used in UDG activity assay
GAC ACG TCA GAT AGC ATG ACA U CG AGC TGC AGG ACT GAT CT
AGA TCA GTC CTG CAG CTC GA T GTC ATG CTA TCT GAC GTG TC
AGA TCA GTC CTG CAG CTC GT T GTC ATG CTA TCT GAC GTG TC
AGA TCA GTC CTG CAG CTC GG T GTC ATG CTA TCT GAC GTG TC
AGA TCA GTC CTG CAG CTC GC T GTC ATG CTA TCT GAC GTG TC
The oligo-U was 5' end radiolabelled with γ-32P ATP. A 100 μl reaction volume containing 70 mM Tris–HCl pH 7.6, 10 mM MgCl2, 5 mM DTT, 1 unit T4 polynucleotide kinase (New England BioLabs, MA, USA), 20 pmol γ-32P ATP (Perkin Elmer, MA, USA) and 200 pmol oligo-U, was incubated at 37°C for 30 min. The reaction was terminated by heating the mixture at 65°C for 20 min. The double stranded substrates were prepared by annealing 100 pmol of 32P-labelled single stranded oligo-U to single stranded oligo-A, -T, -C, and -G in 50 μl reaction volumes containing 70 mM Tris–HCl pH 7.6, 10 mM MgCl2, and 5 mM DTT. The reactions were initially heated at 95°C for 5 min and allowed to cool to room temperature for 3 hr.
Enzymatic assay and biochemical characterization
The UDG activity assay (20 μl) consisted of standard reaction buffer containing 20 mM Tris–HCl pH 8.0, 1 mM DTT, 1 mM EDTA, 50 mM NaCl, 100 μg/ml BSA, 10 pmol 32P-labelled oligo-U, and 20 ng of PfUDG at 37°C for 20 min. The glycosylase activity was stopped by heating at 100°C for 1 min, the resulting apurinic/apyrimidinic site (AP site) was incised by hot alkaline treatment with 0.1 M NaOH (final concentration) at 95°C for 10 min, and the reaction was neutralized with 0.1 M HCl (final concentration). The AP lyase activity assay of PfUDG was examined under the same condition as UDG activity assay except without hot alkaline treatment. Reaction products were analysed on 8 M urea-16% denaturing PAGE and exposed to X-ray film for autoradiography for visualization. The radioactive intensity of sliced substrate and product bands from the gel were measured in a 1450 MicroBeta® Trilux Liquid Scintillation Counter (Perkin Elmer) as counts per minute (cpm). The amounts of substrate and product (pmol) were determined from radioactive intensity. One unit of activity is defined as the amount of PfUDG required for releasing 1 pmol of uracil in 1 min at 37°C in standard reaction buffer (20 mM Tris–HCl pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and 100 μg/ml BSA) with 32P-labelled single stranded oligo-U substrate.
Biochemical properties of native and recombinant PfUDGs were characterized based on UDG activity under different reaction conditions including temperature, pH, salt concentration, cofactors, and substrate preference. The effects of various temperatures ranging from 4-65°C on enzyme activity were tested. PfUDG was also tested at different buffer conditions: phosphate-citrate buffer for pH 4–7, 20 mM Tris–HCl for pH 7.5-8.5, and glycine-NaOH buffer for pH 9–10.5. Effects of NaCl on PfUDG were investigated by using various NaCl concentrations (5–500 mM). In addition, various concentrations of divalent cation cofactors including MgCl2, MnCl2, and CaCl2 at 1, 10, 50, and 100 mM were tested. Relative activity of PfUDG was determined as above by radioactive intensity (cpm) of product divided by total cpm of substrate and product.
To determine steady state kinetic parameters (Km, Vmax) for different substrates of the recombinant PfUDG, concentrations of 32P-labelled substrates were varied from 0.01 to 3.5 μM. The reaction was initiated by adding 2.5 nM PfUDG (2 ng) to the reaction mixture and incubated at 37°C for 10 min. The kinetic parameters, Km and kcat, were calculated based on the Michaelis-Menten equation using non-linear least square algorithm in SigmaPlot 12.0.
Inhibitory effects of UDG inhibitors on PfUDG
Two types of UDG inhibitors, UGI protein and synthetic uracil-derived compounds, were tested for their inhibitory effects on PfUDG. UGI protein of B. subtilis bacteriophage PBS1 (New England BioLabs) was used against native and recombinant PfUDG with 10 pmol 32P-labelled single stranded oligo-U in the standard reaction buffer at 37°C for 20 min. The synthetic uracil-derived compounds were also used at various concentrations (5–640 μM) with 20 ng of recombinant PfUDG and 10 pmol 32P-labelled single stranded oligo-U in the standard reaction buffer at 37°C for 20 min. The same 0.4% (v/v final concentration) of DMSO was used as solvent control to determine its effects on enzyme activity. The dose–response curves of relative activities of PfUDG and various compound concentrations were generated, and half-maximal inhibitory concentration (IC50), the concentration of compound to inhibit enzyme activity by 50%, was obtained using SigmaPlot 12.0.
Inhibition of parasite growth using an in vitro assay
The synchronized ring stage of P. falciparum K1 strain was prepared from mixed stage parasite culture by 5% D-sorbitol treatment. The ring stage parasite was then mixed with culture medium containing RPMI 1640 supplemented with 10% human serum. Various concentrations of each uracil-derived compound were tested at 2-fold serial dilutions in triplicate. Their inhibitory effects on parasite growth were determined by SYBR Green I based assay . The fluorescent intensity was measured by Varioskan Flash Multimode Reader (Thermo Scientific, Vantaa, Finland) with excitation and emission wavelengths of 485 and 535 nm, respectively. The percentage of fluorescent intensity at each compound concentration compared with negative control was indicative of the parasite growth. The dose–response curves of fluorescent intensity and compound concentrations were generated, and IC50, the concentration of compound to inhibit parasite growth by 50%, was obtained using SigmaPlot 12.0.
Cytotoxicity test of active uracil-derived compounds
The uracil-derived compounds showing inhibitory effects on PfUDG were assayed for cytotoxicity to human Caucasian hepatocyte carcinoma cell line ATCC HB 8665 (HepG2) by in vitro cytotoxicity test . The methylthiazol tetrazolium (MTT)-dye based colorimetric microtitration assay was used for detecting cell survival based on the metabolism of tetrazolium to formazan by viable cells. The OD of formazan was measured by a Molecular Devices Microplate Reader (Molecular Devices, CA, USA) at a wavelength of 570 nm. The OD570 represented the cell survival, and the percentage of cell survival at each compound concentration was determined by comparing with the OD570 of negative control lacking compounds. The dose–response curves of % cell survival, and compound concentrations and IC50 were obtained. IC50 representing the concentration of compounds providing 50% cell survival indicated the cytotoxicity of compounds.
Partial purification of PfUDG from parasite crude extract
Partial purification of native PfUDG
Total protein (mg)
Total activity (unit)
Nucleotide and amino acid sequences analysis of PfUDG
Amino acid sequence similarity of PfUDG K1 compared with UDGs from other organisms
Accession numbers of NCBI protein reference sequence
P. falciparum 3D7
P. falciparum IT
Homo sapiens (hUNG2)
Homo sapiens (hUNG1)
E. coli K12
Saccharomyces cerevisiae S288
Mus musculus isoform A
Mus musculus isoform B
T. cruzi CL Brener
Herpes simplex virus type 1
Herpes simplex virus type 2
Expression and purification of recombinant PfUDG
Identification of PfUDG by LC-MS/MS and 3D modelling of PfUDG
The 3D structure was built from the 214 amino acid sequence of PfUDG K1 using human UDG as a template (Figure 3B). This structure presented 8 α helices and 4 paralled β sheets. The active site motif I (Gly167, Gln168, Asp169, Pro170, Tyr171, and His172) was located at a loop connecting β1 strand and α4 and motif II was located at the loop linking β4 strand and α8 near the C terminus of the enzyme. A single amino acid different at Pro157 for P. falciparum strain 3D7 compared to Thr157 of P. falciparum strain K1 is located at the loop connecting the α3 and β1 strands. Stereochemical quality of the PfUDG structure generated was validated by PROCHECK and presented as Ramachandran Plot determined from degree of Phi and Psi angles of each amino acid residue. The result demonstrated 90.2% amino acid residues in the most favoured region, 8.2% for additional allowed region, 1.5% for generously allowed region, and 0.0% for disallowed region. Moreover, the root mean square deviation of PfUDG K1 model was 1.18 compared to the template analysed by Swiss-PdbViewer Software suggesting the appropriate structure of the PfUDG modelled.
Enzymatic activity and biochemical characterization
Kinetic parameters of recombinant PfUDG
2.2 ± 0.2
2,768 ± 105
0.7 ± 0.1
137 ± 4
Inhibitory effects of inhibitors on PfUDG activity, parasite growth and their cytotoxicity
Comparisons of IC 50 s of uracil-derived compounds in their inhibitory effects on recombinant PfUDG activity, P. falciparum growth and cytotoxicity to HepG2 cell lines
27.5 ± 4.58
Usually, UDG works as the key enzyme in the BER pathway to recognize the uracil base occurring abnormally during DNA replication [42, 43]. Uracil causing G:C to A:T transition mutations in DNA is harmful to essential genes of all organisms. Because this enzyme acts in the primary step to direct further steps of the DNA repair pathway, inhibition of this enzyme would affect DNA repair of P. falciparum and eventually may lead to parasite death.
In this study, the existence and activity of PfUDG was firstly confirmed by isolation and partial purification of the native PfUDG from parasite extracts using anion exchange and Heparin Sepharose chromatography. The late trophozoites and schizonts were used in this experiment, because they are involved in cell division in which incorrect DNA replication should occur frequently; DNA repair is essential for maintenance of genome integrity during DNA replication to prevent mutation. The frequency of generated uracil in parasite DNA should be high during DNA replication similar to other organisms including human [19, 43].
Since the calculated pI value of PfUDG is rather high (pI 9.78), finding PfUDG in a flow through fraction when using an anion exchange column with buffer system at pH 9 was expected. This step was efficient as 50% UDG activity was recovered, while a large amount of other proteins was removed (Table 2). After using two columns, we could not further purify PfUDG to near homogeneity due to the low amount of enzyme activity, instability during subsequent purification steps even in the presence of protease inhibitors, and lack of an affinity column for UDG purification. In addition, cultivation of P. falciparum was laborious and much more medium, human red blood cells and serum would be required to obtain a higher amount of parasites. Therefore, heterologous expression of PfUDG was an option pursued in this study.
Escherichia coli is among the most widely used hosts for heterologous protein production due to its fast growth rate in cheap media, known genetic property, and ease of use and genetic manipulation. However, expression of Plasmodium proteins in E. coli can sometimes be challenging [44, 45]. Expression of PfUDG in a general expression BL21 DE3 host yielded PfUDG mostly as an insoluble protein. However, Rosetta (DE3) pLysS - a BL21 derivative harbouring extra copies of rare tRNAs for codons AUA (Ile), AGG (Arg), AGA (Arg), CUA (Leu), CCC (Pro), and GGA (Gly) significantly improved PfUDG solubility. These rare codons accounted for 53% AUA, 75% AGG/AGA, 7% CUA, 17% CCC, and 50% GGA of total codons encoding each amino acid in PfUDG. With the yield of 9 mg/L culture obtained via the optimized expression and purification protocols, other downstream studies such as biochemical characterization and inhibitor screening could be facilitated. However, a faint band of incomplete protein was observed during protein expression as a ~30-kDa protein (Figure 2). This may be a degraded or truncated form caused by the over-expression of recombinant protein in the E. coli host, based on degradation of excess protein by bacterial enzymes. Therefore, bacteria may not be the best expression host for eukaryote PfUDG expression, and the use of a eukaryote expression host should improve the quality and yield of protein expression.
It should be mentioned that sequence comparisons among different P. falciparum strains revealed Thr/Pro157 polymorphism. Although Proline is present in other strains, various amino acids including Threonine are observed in other UDGs, suggesting that this polymorphism is unlikely to affect enzyme catalysis. Additionally, this residue is located distantly from the active site based on the PfUDG modelled structure.
Based on a 3D structure of the recombinant PfUDG, PfUDG was similar to other organisms as it contains 8 α-helices and 4-paralled β strands . The two active site motifs are located in positions similar to other UDGs: motif I located at the loop connecting β1 strand and α4 helix, and motif II located at the connecting loop of β4 strand and α8 helix. The stereochemical quality of the PfUDG structure, which was validated by PROCHECK, confirmed that the modelled structure is suitable for study of the molecular interaction between enzyme and inhibitors.
Biochemical properties such as assay condition, substrate preference, and enzyme inhibition by UGI of native and recombinant PfUDGs were characterized. PfUDG is a heat-labile enzyme, and the optimal temperature of both native and recombinant PfUDG was the same at 37°C. This is the physiological temperature of human hosts of parasites. This optimal temperature was similar to that for UDG from other organisms except T. cruzi UDG, which showed optimal temperature at 45°C . Both forms of PfUDG worked well in alkaline conditions (pH 7–9), so it is suggested to be one of the pH-dependent enzymes. This result relates to the optimal pH of UDG from other organisms [20, 24, 27].
The optimal NaCl concentrations for both native and recombinant PfUDGs were 50–75 mM, which are in the same range of UDG from other organisms, for example 50 mM in hUNG2  and 65 mM in T. cruzi UDG . The enzyme activity was significantly decreased at higher NaCl concentrations. The high concentrations of neutral salts can produce high ionic strength that inhibits the activity of many enzymes .
For the cofactor requirement, the native and recombinant PfUDGs worked effectively without any divalent cation cofactors including Mg2+, Mn2+ and Ca2+. Our results were similar to those for E. coli UDG that did not require any cofactors for its function [20, 21] while UDG of human , vaccinia virus  and HSV-2  showed activity with optimal MgCl2 at 6 mM, 7.5 mM and 5 mM, respectively. Therefore, PfUDG is suggested as a cofactor-independent enzyme which is significantly different from the human enzyme. High concentrations of divalent cations were suggested to induce structural changes or interact directly with negatively charged groups of the enzyme . The native and recombinant PfUDGs functioned at comparable assay conditions; however, it was noted that the recombinant enzyme showed a broader tolerant range of assay conditions.
Based on the results obtained that PfUDG possesses uracil glycosylase activity for both ss-U and ds-A:U but lacks AP lyase activity, PfUDG belongs to UDG-family I . In human, uracil found in double stranded DNA is generated via cytosine deamination, while that seen in single stranded DNA is due to misincorporation of the nucleotide at the replication fork during DNA replication . Unlike the human enzyme (hUNG2), PfUDG exhibited similar catalytic efficiency (kcat/Km) toward ss-U and ds-A:U. The data suggests that PfUDG can serve to remove uracil resulting from deamination damage and misincorporation during DNA replication to prevent gene mutation in the malarial parasite.
Both enzymes were inhibited by UGI protein of bacteriophage PBS1 specific to B. subtilis similar to UDG from other organisms [28–31, 50]. Therefore, the recombinant enzyme is functionally comparable to the native counterpart and can replace the native enzyme for further studies such as inhibitor screening.
PfUDG was inhibited by two uracil-derived compounds: 1-methoxyethyl-6-(p-n-octylanilino)uracil showed a greater inhibitory effect (IC50 16.75 μM) than 6-(phenylhydrazino)uracil (IC50 77.5 μM). Some of the tested compounds were previously studied for their inhibitory effects on HSV-1 UDG purified from HSV-1-infected HeLa cells and purified human HeLa UDG and they inhibited HSV-1 UDG more than human UDG based on their IC50s . 6-(4-n-Octylanilino)uracil, an analog of 1-methoxyethyl-6-(p-n-octylanilino)uracil) and 6-(4-n-hexylanilino)uracil were used to differentiate HSV-1 and human UDG. Based on our results, four compounds showed no inhibition of PfUDG (IC50 of > 400 μM), but demonstrated inhibition of HSV-1 UDG such as 6-(p-n-butylanilino)uracil (IC50 of 150 μM), 6-(p-n-pentylanilino)uracil (IC50 of 30 μM), 6-(p-i-pentylanilino)uracil (IC50 of 140 μM), and 6-(p-n-heptylanilino)uracil (IC50 of 20 μM) . Therefore, these four compounds can be used to differentiate HSV-1 UDG and PfUDG. This result confirmed that there are some differences between the malarial enzyme (PfUDG) and viral enzyme (HSV-1 UDG). Moreover, 1-methoxyethyl-6-(p-n-octylanilino)uracil exhibited significant inhibitory effects on PfUDG (IC50 of 16.75 μM) while 6-(4-n-octylanilino)uracil showed no inhibitory effects on human UDG (IC50 of > 300 μM) . The 1-methoxyethyl-6-(p-n-octylanilino)uracil and other series of alkylanilinouracils should be further tested for their inhibitory effects on human UDG. Among 12 inhibitors, 1-methoxyethyl-6-(p-n-octylanilino)uracil exhibited the most potent anti-PfUDG activity with anti-malarial activity. Additionally, this compound was not cytotoxic to HepG2 cells (IC50 was 10 folds greater than that of P. falciparum). The data here indicate the dissimilar binding sites between the parasite and human enzymes, hence rational design for a selective inhibitor against PfUDG can be achieved. Furthermore, 1-methoxyethyl-6-(p-n-octylanilino)uracil can serve as a starting template for development of new antiplasmodial agents. Molecular docking of this analog and PfUDG in comparison to that of human enzyme is being explored to reveal the distinct binding modes and molecular interactions between these enzymes and inhibitor to aid the rational drug design.
The native and recombinant PfUDGs were characterized for biochemical properties. Results demonstrated that there is no significant difference between them. Therefore, recombinant PfUDG can be used to screen for active compounds targeting this parasite enzyme. The recombinant enzyme was inhibited by two uracil-derived compounds, 1-methoxyethyl-6-(p-n-octylanilino)uracil and 6-(phenylhydrazino)uracil, and these compounds inhibited parasite growth. The first compound was not toxic to HepG2 cell lines while the latter one was cytotoxic. These results indicate that PfUDG may act as a good target against malaria, and newly synthesized uracil-derived compounds should be further developed to have the most effective and least toxic anti-malarial drug in the future.
We thank Dr. Sittiruk Roytrakul, at the National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency (NSTDA), Pathumthani, Thailand, for facilitating the LC-MS/MS and software analysis, Assoc. Prof. Col Mathirut Mungthin, at the Department of Parasitology, Pramongkutklao College of Medicine, Bangkok, Thailand, for facilitating the Liquid Scintillation Counter equipment, and Ms. Kanthinich Thima at the Department of Protozoology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, for technical assistance in parasite culture. This study was financially supported by the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative and Thailand Graduate Institute of Science and Technology (TGIST 01-52-006) under NSTDA for TS.
- WHO: World Malaria Report 2012. 2012, Geneva: World Health Organization,http://who.int/malaria/publications/world_malaria_report_2012/report/en/,Google Scholar
- Noedl H, Se Y, Schaccher K, Smith BL, Socheat D, Fukuda MM: Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008, 359: 2619-2620. 10.1056/NEJMc0805011.View ArticlePubMedGoogle Scholar
- Dondrop AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859.View ArticleGoogle Scholar
- Adhin MR, Labadie-Bracho M, Vreden SG: Status of potential PfATP6 molecular markers for artemisinin resistance in Suriname. Malar J. 2012, 11: 322-10.1186/1475-2875-11-322.PubMed CentralView ArticlePubMedGoogle Scholar
- Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM: Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012, 12: 851-858. 10.1016/S1473-3099(12)70181-0.PubMed CentralView ArticlePubMedGoogle Scholar
- Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, Hanpithakpong W, Stepniewska K, Menard D, Ringwald P, Silamut K, Imwong M, Chotivanich K, Yi P, Day NP, Lindegardh N, Socheat D, Nguon C, White NJ, Nosten F, Dondorp AM: Effect of high dose or split dose artesunate on parasite clearance in artemisinin resistant falciparum malaria. Clin Infect Dis. 2013, 56: 48-58. 10.1093/cid/cis958.View ArticleGoogle Scholar
- Calas M, Ancelin ML, Cordina G, Portefaix P, Piquet G, Vidal-Sailhan V, Vial H: Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem. 2000, 43: 505-515. 10.1021/jm9911027.View ArticlePubMedGoogle Scholar
- Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, Calas M, Herrera S, Thomas AW, Vial HJ: A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science. 2002, 295: 1311-1314. 10.1126/science.1067236.View ArticlePubMedGoogle Scholar
- Joet T, Eckstein-Ludwig U, Morin C, Krishna S: Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc Natl Acad Sci U S A. 2003, 100: 7476-7479. 10.1073/pnas.1330865100.PubMed CentralView ArticlePubMedGoogle Scholar
- Bailly E, Jambou R, Savel J, Jaureguiberry G: Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor). J Protozool. 1992, 39: 593-599. 10.1111/j.1550-7408.1992.tb04856.x.View ArticlePubMedGoogle Scholar
- Salmon BL, Oksman A, Goldberg DE: Malaria parasite exit from the host erythrocyte: a two-step process requiring extraerythrocytic proteolysis. Proc Natl Acad Sci U S A. 2001, 98: 271-276. 10.1073/pnas.98.1.271.PubMed CentralView ArticlePubMedGoogle Scholar
- Naughton JA, Nasizadeh S, Bell A: Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol. 2010, 173: 81-87. 10.1016/j.molbiopara.2010.05.007.View ArticlePubMedGoogle Scholar
- Wang PF, Arscott LD, Gilberger TW, Muller S, Williams CH: Thioredoxin reductase from Plasmodium falciparum: evidence for interaction between the C-terminal cysteine residues and the active site disulfide-dithiol. Biochemistry. 1999, 38: 3187-3196. 10.1021/bi982674g.View ArticlePubMedGoogle Scholar
- Krauth-Siegel RL, Coombs GH: Enzymes of parasite thiol metabolism as drug targets. Parasitol Today. 1999, 15: 404-409. 10.1016/S0169-4758(99)01516-1.View ArticlePubMedGoogle Scholar
- Krungkrai J, Krungkrai SR, Suraveratum N, Prapunwattana P: Mitochondrial ubiquinol-cytochrome c reductase and cytochrome c oxidase: chemotherapeutic targets in malarial parasites. Biochem Mol Biol Int. 1997, 42: 1007-1014.PubMedGoogle Scholar
- Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malaria parasite. J Biol Chem. 1997, 272: 3961-3966. 10.1074/jbc.272.7.3961.View ArticlePubMedGoogle Scholar
- Krokan HE, Standal R, Slupphaug G: DNA glycosylases in the base excision repair of DNA. Biochem J. 1997, 325: 1-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson DM, Bohr VA: The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair. 2007, 6: 544-559. 10.1016/j.dnarep.2006.10.017.View ArticlePubMedGoogle Scholar
- Lindahl T: Instability and decay of the primary structure of DNA. Nature. 1993, 362: 709-715. 10.1038/362709a0.View ArticlePubMedGoogle Scholar
- Lindahl T: An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues. Proc Natl Acad Sci U S A. 1974, 71: 3649-3653. 10.1073/pnas.71.9.3649.PubMed CentralView ArticlePubMedGoogle Scholar
- Lindahl T, Ljungquist S, Siegert W, Nyberg B, Sperens B: DNA N-glycosidases: properties of uracil-DNA glycosidase from Escherichia coli. J Biol Chem. 1977, 252: 3286-3294.PubMedGoogle Scholar
- Stuart DT, Upton C, Higman MA, Niles EG, McFadden G: A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. J Virol. 1993, 67: 2503-2512.PubMed CentralPubMedGoogle Scholar
- Argnani R, Focher F, Zucchini S, Verri A, Wright GE, Spadari S, Manservigi R: Herpes simplex virus type 1 (HSV-1) uracil-DNA glycosylase: functional expression in Escherichia coli, biochemical characterization, and selective inhibition by 6-(p-n-octylanilino)uracil. Virology. 1995, 211: 307-311. 10.1006/viro.1995.1406.View ArticlePubMedGoogle Scholar
- Peña-Diaz J, Akbari M, Sundheim O, Farez-Vidal ME, Andersen S, Sneve R, Gonzalez-Pacanowska D, Krokan HE, Slupphaug G: Trypanosoma cruzi contains a single detectable uracil-DNA glycosylase and repairs uracil exclusively via short patch base excision repair. J Mol Biol. 2004, 342: 787-799. 10.1016/j.jmb.2004.07.043.View ArticlePubMedGoogle Scholar
- Slupphaug G, Olsen LC, Helland D, Aasland R, Krokan HE: Cell cycle regulation and in vitro hybrid arrest analysis of the major human uracil-DNA glycosylase. Nucleic Acids Res. 1991, 19: 5131-5137. 10.1093/nar/19.19.5131.PubMed CentralView ArticlePubMedGoogle Scholar
- Visnes T, Doseth B, Pettersen HS, Hagen L, Sousa MM, Akbari M, Otterlei M, Kavli B, Slupphaug G, Krokan HE: Uracil in DNA and its processing by different DNA glycosylases. Philos Trans R Soc Lond B Biol Sci. 2009, 364: 563-568. 10.1098/rstb.2008.0186.PubMed CentralView ArticlePubMedGoogle Scholar
- Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, Skorpen F, Aas PA, Hagen L, Krokan HE, Slupphaug G: hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in Single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem. 2002, 277: 39926-39936. 10.1074/jbc.M207107200.View ArticlePubMedGoogle Scholar
- Bennett SE, Schimerlik MI, Mosbaugh DW: Kinetics of the uracil-DNA glycosylase/inhibitor protein association. Ung interaction with Ugi, nucleic acids, and uracil compounds. J Biol Chem. 1993, 268: 26879-26885.PubMedGoogle Scholar
- Scaramozzino N, Sanz G, Crance JM, Saparbaev M, Drillien R, Laval J, Kavil B, Garin D: Characterization of the substrate specificity of homogeneous vaccinia virus uracil-DNA glycosylase. Nucleic Acids Res. 2003, 31: 4950-4957. 10.1093/nar/gkg672.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu CC, Huang HT, Wang JT, Slupphaug G, Li TK, Wu MC, Chen YC, Lee CP, Chen MR: Characterization of the uracil-DNA glycosylase activity of Epstein-Barr virus BKRF3 and its role in lytic viral DNA replication. J Virol. 2007, 81: 1195-1208. 10.1128/JVI.01518-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakamura N, Morinaga H, Kikuchi M, Yonekura SI, Ishii N, Yamamoto K, Yonei S, Zhang QM: Cloning and characterization of uracil-DNA glycosylase and the biological consequences of the loss of its function in the nematode Caenorhabditis elegans. Mutagenesis. 2008, 23: 407-413. 10.1093/mutage/gen030.View ArticlePubMedGoogle Scholar
- Sun H, Zhi C, Wright GE, Ubiali D, Pregnolato M, Verri A, Focher F, Spadari S: Molecular modelling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase. J Med Chem. 1999, 42: 2344-2350. 10.1021/jm980718d.View ArticlePubMedGoogle Scholar
- Focher F, Verri A, Spadari S, Manservigi R, Gambino J, Wright GE: Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives. Biochem J. 1993, 292: 883-889.PubMed CentralView ArticlePubMedGoogle Scholar
- Thaithong S, Beale GH, Chutmongkonkul M: Susceptibility of Plasmodium falciparum to five drugs: and in vitro study of isolates mainly from Thailand. Trans R Soc Trop Med Hyg. 1983, 77: 228-231. 10.1016/0035-9203(83)90080-9.View ArticlePubMedGoogle Scholar
- Lasonder E, Ishihama Y, Andersen JS, Vermunt AMW, Pain A, Sauerwein RW, Eling WMC, Hall N, Waters AP, Stunnenberg HG, Mann M: Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature. 2002, 419: 537-542. 10.1038/nature01111.View ArticlePubMedGoogle Scholar
- Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006, 22: 195-201. 10.1093/bioinformatics/bti770.View ArticlePubMedGoogle Scholar
- Bordoli L, Kiefer F, Arnold K, Benkert P, Battery J, Schwede T: Protein structure homology modelling using SWISS-MODEL workspace. Nat Protoc. 2009, 4: 1-13.View ArticlePubMedGoogle Scholar
- Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T: The SWISS-MODEL Repository and assaociated resources. Nucleic Acids Res. 2009, 37: D387-D392. 10.1093/nar/gkn750.PubMed CentralView ArticlePubMedGoogle Scholar
- Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM: AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996, 8: 477-486.View ArticlePubMedGoogle Scholar
- Rason MA, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D: Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg. 2008, 104: 346-351.View ArticleGoogle Scholar
- Plumb JA, Milroy R, Kaye SB: Effects of the pH dependence of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989, 49: 4435-4440.PubMedGoogle Scholar
- Franklin A, Blanden RV: On the molecular mechanism of somatic hypermutation of rearranged immunoglobulin genes. Immunol Cell Biol. 2004, 82: 557-567. 10.1111/j.1440-1711.2004.01289.x.View ArticlePubMedGoogle Scholar
- Huffman JL, Sundheim O, Tainer JA: DNA base damage recognition and removal: new twists and grooves. Mutat Res. 2005, 577: 55-76. 10.1016/j.mrfmmm.2005.03.012.View ArticlePubMedGoogle Scholar
- Dabrowski S, Kiaer Ahring B: Cloning, expression, and purification of the His6-tagged hyper-thermostable dUTPase from Pyrococcus woesei in Escherichia coli: application in PCR. Protein Expr Purif. 2003, 31: 72-78. 10.1016/S1046-5928(03)00108-6.View ArticlePubMedGoogle Scholar
- Siribal S, Weinfeld M, Karimi-Busheri F, Mark Glover JN, Bernstein NK, Aceytuno D, Chavalitshewinkoon-Petmitr P: Molecular characterization of Plasmodium falciparum putative polynucleotide kinase/phosphatase. Mol Biochem Parasitol. 2011, 180: 1-7. 10.1016/j.molbiopara.2011.06.007.View ArticlePubMedGoogle Scholar
- Pearl LH: Structure and function in the uracil-DNA glycosylase superfamily. Mutat Res. 2000, 460: 165-181. 10.1016/S0921-8777(00)00025-2.View ArticlePubMedGoogle Scholar
- Warren JC, Stowring L, Morales MF: The effect of structure-disrupting ions on the activity of myosin and other enzymes. J Biol Chem. 1966, 241: 309-316.PubMedGoogle Scholar
- Winters TA, Williams MV: Purification and characterization of the herpes simplex virus type 2-encoded uracil-DNA glycosylase. Virology. 1993, 195: 315-326. 10.1006/viro.1993.1382.View ArticlePubMedGoogle Scholar
- Akhtar MS, Ahmad A, Bhakuni V: Divalent cation induced changes in structural properties of the dimeric enzyme glucose oxidase: dual effect of dimer stabilization and dissociation with loss of cooperative interactions in enzyme monomer. Biochemistry. 2002, 41: 7142-7149. 10.1021/bi020080e.View ArticlePubMedGoogle Scholar
- Khattar SK, Van Drunen Littel-Van Den Hurk S, Babiuk LA, Tikoo SK: Identification and transcriptional analysis of a 3'-coterminal gene cluster containing UL1, UL2, UL3, and UL3.5 open reading frames of bovine herpesvirus-1. Virology. 1995, 213: 28-37. 10.1006/viro.1995.1543.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.